MEDI4736 + Tremelimumab + MEDI4736 + Tremelimumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Conditions
Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Trial Timeline
Apr 15, 2015 → Jul 6, 2020
NCT ID
NCT02319044About MEDI4736 + Tremelimumab + MEDI4736 + Tremelimumab
MEDI4736 + Tremelimumab + MEDI4736 + Tremelimumab is a phase 2 stage product being developed by AstraZeneca for Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck. The current trial status is completed. This product is registered under clinical trial identifier NCT02319044. Target conditions include Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02319044 | Phase 2 | Completed |
Competing Products
4 competing products in Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Drug Combination Therapy | Sun Pharmaceutical | Phase 2 | 52 |
| pepinemab + pembrolizumab | Merck | Phase 1/2 | 41 |
| Pembrolizumab + Cisplatin + Carboplatin + Gemcitabine | Merck | Phase 2 | 52 |
| Nivolumab + Paclitaxel + Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 51 |